Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Tao Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7094-6868; OpenAlex author ID A5100654768. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 12

  1. The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling. Co-author DOI 10.3390/cancers15225454↗
  2. A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy. Co-author DOI 10.2147/dddt.s366558↗
  3. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Co-author DOI 10.1038/s41388-021-01763-z↗
  4. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  5. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  6. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Co-author DOI 10.1016/j.biomaterials.2018.11.035↗
  7. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.009↗
  8. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
  9. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Co-author DOI 10.1016/j.canlet.2018.08.010↗
  10. Liquid biopsy in pancreatic cancer: the beginning of a new era. Co-author DOI 10.18632/oncotarget.24809↗
  11. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. First author DOI 10.1016/j.canlet.2017.07.012↗
  12. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Co-author DOI 10.1158/0008-5472.can-16-3143↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 8 shared papers, 2018–2021 · strength 0.71
  2. Xueli Bai · 5 shared papers, 2019–2021 · strength 0.47
  3. Xiang Li · 5 shared papers, 2017–2020 · strength 0.40
  4. Risheng Que · 5 shared papers, 2017–2020 · strength 0.40
  5. Xiao Zhi · 3 shared papers, 2018–2020 · strength 0.25
  6. Lei Zheng · 3 shared papers, 2017–2019 · strength 0.22
  7. Jiayi Chen · 1 shared paper, 2022 · strength 0.20
  8. Haoping Xu · 1 shared paper, 2022 · strength 0.20
  9. Qi Zhang · 2 shared papers, 2020 · strength 0.19
  10. Tao Wei · 2 shared papers, 2019–2020 · strength 0.18
  11. Wei Chen · 2 shared papers, 2018–2020 · strength 0.18
  12. Guogang Li · 2 shared papers, 2018–2019 · strength 0.17
  13. Jiaqi Yang · 2 shared papers, 2019–2020 · strength 0.17
  14. Jiancong Xie · 1 shared paper, 2023 · strength 0.17
  15. Tuo Hu · 1 shared paper, 2023 · strength 0.17
  16. Weidong Pan · 1 shared paper, 2023 · strength 0.17
  17. Hao Zhang · 1 shared paper, 2023 · strength 0.17
  18. Jing Chen · 1 shared paper, 2023 · strength 0.17
  19. Jianying Lou · 2 shared papers, 2019 · strength 0.16
  20. Hanshen Yang · 1 shared paper, 2021 · strength 0.12
  21. Yi Duan · 1 shared paper, 2021 · strength 0.12
  22. Jian Xu · 1 shared paper, 2021 · strength 0.12
  23. Xiaozhen Zhang · 1 shared paper, 2021 · strength 0.12
  24. Mengyi Lao · 1 shared paper, 2021 · strength 0.12
  25. Qihan Fu · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.